![]() |
This webpage was last updated on 07/09/011 | ![]() |
| ECRHS | ||
![]() |
||
European Community Respiratory Health Survey
|
||
|
The study was developed in response to the increasing mortality rates associated with asthma in many parts of Europe and elsewhere in the mid 1980s. Also, around this time, evidence emerged of an increase in the prevalence of asthma and allergic disease. Co-ordination of the study was funded by the European Commission, and local data collection by a number of grants. See the link to Funding. Fifty six centres from 25 countries took part in
stage 1 of ECRHS I, and 45 in at least part of stage 2.
Co-ordinating Centre (London): P Burney, S Chinn, C Luczynska, D Jarvis, E Lai. Project Management Group: P Burney (Project leader) S Chinn, C Luczynska, D Jarvis, P Vermeire (Antwerp), H Kesteloot (Leuven), J Bousquet (Montpellier), D Nowak (Hamburg), the late J Prichard (Dublin), R de Marco (Verona), B Rijcken (Groningen), JM Anto (Barcelona), J Alves (Oporto), G Boman (Uppsala), N Nielsen (Copenhagen), P Paoletti (Pisa). Participating Centres: W Popp (Vienna, Austria); M Abramson, J Kutin (Melbourne, Australia); P Vermeire, F van Bastelaer (Antwerp South, Antwerp Central, Belgium); J Bousquet J Knani (Montpellier) F Neukirch, R Liard (Paris) I Pin, C Pison (Grenoble) A Taytard (Bordeaux, France); H Magnussen, D Nowak (Hamburg); H-E Wichmann, J Heinrich (GSF Institute of Epidemiology, Erfurt, Germany); N Papageorgiou, P Avarlis, M Gaga, C Marossis (Athens, Greece); T Gislason D Gislason (Reykjavik, Iceland); J Prichard, S Allwright, D MacLeod (Dublin,Ireland); M Bugiani, C Bucca, C Romano (Turin) R de Marco Lo Cascio, C Campello (Verona) A Marinoni, I Cerveri, L Casali (Pavia, Italy); B Rijcken, A Kremer (Groningen, Bergen-op-Zoom, Geleen, The Netherlands); J Crane, S Lewis (Wellington, Christchurch, Hawkes Bay, New Zealand); A Gulsvik, E Omenaas (Bergen, Norway); JA Marques, J Alves (Oporto, Portugal); Spain: JM Antó, J Sunyer, F Burgos, J Castellsagué, J Roca, JB Soriano, A Tobías (Barcelona), N Muniozguren, J Ramos González, A Capelastegui (Galdakao) J Castillo, J Rodriguez Portal (Seville) J Martinez-Moratalla, E Almar (Albacete) J Maldonado Pérez A Pereira, J Sánchez (Huelva) J Quiros, I Huerta, F Pavo (Oviedo, Spain); G Boman, C Janson, E Björnsson (Uppsala) L Rosenhall, E Norrman B Lundbäck (Umeå) N Lindholm, P Plaschke (Göteborg, Sweden);U Ackermann-Liebrich, N Künzli, A Perruchoud (Basel, Switzerland); M Burr, J Layzell (Caerphilly) R Hall (Ipswich) B Harrison (Norwich) J Stark (Cambridge, UK); S Buist, W Vollmer , M Osborne (Portland, USA)
Main
aims
|
| During
a clinical examination blood was taken for measurement of specific IgE
to house dust mite, cat, grass and Cladosporium (mould) and total
IgE. Forced expiratory volume in one second (FEV1), forced vital capacity
(FVC) and bronchial reactivity to methacholine were measured. In addition,
each centre also assessed a sample of about 150 adults with symptoms highly
suggestive of asthma.
Click on Publications to see a list of all ECRHS published papers. The maps below detail the prevalence of asthma, the prevalence of atopy and the distribution of bronchial hyper-responsiveness based on data collected in ECRHS I. Complete information was not available for all centres. |
![]() |
![]() |
![]() |
ECRHS II was a nine year follow-up
prospective survey of more than 10,000 young adults which began in 1998.
It was a collaborative study and aimed to collect data from 29 centres
in 14 countries (mostly European). The study was funded by the European
Commission, as well as other sources, as part of their Quality of Life
Programme. Major papers have already been published, and many more are
in preparation by Working Groups. See link
to Publications. The aims of ECRHS II were:
1. To determine the incidence and prognosis of allergy, allergic disease (asthma, hayfever and eczema) and low lung function in adults.
2. To describe the distribution of exposure to known or suspected environmental risk factors associated with the incidence and prognosis of allergy, allergic disease and low lung function.
3. To determine the risk attributable to chronic exposure to these environmental risk factors for the incidence and prognosis
of allergy, allergic disease and low lung function.
4. To identify subgroups within the population based on gender, prior disease status, bronchial responsiveness and genetic risk who may be more susceptible to these environmental risk factors and measure their excess risk.
5. To establish a bank of blood samples suitable for DNA extraction taken from representative samples of the population that can be linked to health and environmental information.
In ECRHS II, in 29 centres, individuals who took part in the clinical stage of ECRHS I were sent a short screening questionnaire and hose who responded were invited to a local fieldwork centre, situated in an outpatient or lung function laboratory in a local hospital or centre. Environmental information was collected by home visits in a subsample of homes, and past and current exposure to air pollution was assessed through retrieval of air pollution records and by a programme of air pollution monitoring.
In the fieldwork centre the following procedures were performed:
Detailed administered questionnaire asking about symptoms, exposure to known or suspected risk factors for asthma, and health service utilisation;
Self completion of the SF-36, a validated and widely used quality of life questionnaire, and AQLQ, a disease-specific measure of quality of life;
Venepuncture - blood was taken for measurement of specific IgE to house dust mite, grass, cat and Cladosporium, as well as total IgE; in some centres samples were stored for later use in DNA studies;
Measurement of lung function (FEV1 and FVC);
Bronchial challenge testing. |